Serum levels of circulating miRNA-21, miRNA-10b and miRNA-200c in triple-negative breast cancer patients
Abstract
Introduction: Breast cancer can be classified into five subtypes based on variations in the status of three hormonal receptors that are responsible for the cancer’s heterogeneity: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These classifications influence the choice of therapies (either neoadjuvant or adjuvant), and the range of prognoses, from good (luminal A subtype) to poor (triple-negative cancers).
Objective: The aim of the study was to compare the serum concentration of selected miRNAs (miRNA-21, miRNA-10b, and miRNA-200c) between in two groups of breast cancer patients with differing ER, PR, and HER2 statuses.
Materials and methods: The study was performed on two groups of patients. One group (TNBC) consisted of patients with triple-negative cancer, and the other group (ER(+)/PR(+)) was comprised of patients with positive ER and PR receptors.
Results: The mean level of miRNA-200c was significantly higher in the ER(+)/PR(+) group than in the TNBC group (p < 0.05). No statistically significant difference was found between the two groups with regard to the mean levels of miRNA-21 or miRNA-10b.
Conclusion: The level of miRNA-200c was lower in triple-negative patients when compared with the levels in the study’s ER/PR positive group.
Keywords: miRNAbreast cancerreceptorsbiomarkertriple negative
References
- Ferlay J, Shin HR, Bray F et al. DM.GLOBOCAN 2008 v1.2, cancer incidence and mortality worldwide: IARC cancer base no. 10 [internet]. Lyon, France: International Agency for Research on Cancer, 2010. http://globocan.iarc.fr (05.2011).
- Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406(6797): 747–752.
- Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19): 10869–10874.
- van 't Veer LJ, Dai H, van de Vijver MJ, et al. Expression profiling predicts outcome in breast cancer. Breast Cancer Res. 2003; 5(1): 57–58.
- Geiger T, Madden SF, Gallagher WM, et al. Proteomic portrait of human breast cancer progression identifies novel prognostic markers. Cancer Res. 2012; 72(9): 2428–2439.
- Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1): 15–20.
- Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res. 2005; 65(9): 3509–3512.
- Fu S, Chen L, Man Yg. miRNA Biomarkers in Breast Cancer Detection and Management. Journal of Cancer. 2011; 2: 116–122.
- Sempere LF, Christensen M, Silahtaroglu A, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007; 67(24): 11612–11620.
- Ibrahim SA, Yip GW, Stock C, et al. Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism. Int J Cancer. 2012; 131(6): E884–E896.
- Korpal M, Lee ES, Hu G, et al. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem. 2008; 283(22): 14910–14914.
- Anfossi S, Giordano A, Gao H, et al. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One. 2014; 9(1): e83113.
- Yan LX, Huang XF, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008; 14(11): 2348–2360.
- Gao J, Zhang Q, Xu J, et al. Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chin J Cancer Res. 2013; 25(6): 743–748.
- Tanaka K, Tokunaga E, Inoue Y, et al. Impact of expression of vimentin and axl in breast cancer. Clin Breast Cancer. 2016; 16(6): 520–526.e2.
- Wang F, Zheng Z, Guo J, et al. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol. 2010; 119(3): 586–593.
- Heneghan HM, Miller N, Lowery AJ, et al. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg. 2010; 251(3): 499–505.
- Mattie MD, Benz CC, Bowers J, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006; 5: 24.
- Qian B, Katsaros D, Lu L, et al. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1. Breast Cancer Res Treat. 2009; 117(1): 131–140.
- Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16): 7065–7070.
- Heneghan HM, Miller N, Kelly R, et al. MicroRNAs as Novel Biomarkers for Breast Cancer. J Oncol. 2009; 2009(3): 950201–505.
- Hagrass HA, Sharaf S, Pasha HF, et al. Circulating microRNAs — a new horizon in molecular diagnosis of breast cancer. Genes Cancer. 2015; 6(5-6): 281–287.
- Radojicic J, Zaravinos A, Vrekoussis T, et al. MicroRNA expression analysis in triple-negative (ER, PR and Her2/neu) breast cancer. Cell Cycle. 2011; 10(3): 507–517.
- Abrahamsson A, Dabrosin C. Tissue specific expression of extracellular microRNA in human breast cancers and normal human breast tissue in vivo. Oncotarget. 2015; 6(26): 22959–22969.
- Kodahl AR, Lyng MB, Binder H, et al. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol. 2014; 8(5): 874–883.
- Ouyang M, Li Y, Ye S, et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One. 2014; 9(5): e96228.
- Ma Li, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163): 682–688.
- Wu X, Somlo G, Yu Y, et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med. 2012; 10: 42.
- Berber U, Yilmaz I, Narli G, et al. miR-205 and miR-200c: Predictive Micro RNAs for Lymph Node Metastasis in Triple Negative Breast Cancer. J Breast Cancer. 2014; 17(2): 143–148.
- Kolacinska A, Morawiec J, Pawlowska Z, et al. Association of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients. DNA Cell Biol. 2014; 33(9): 624–629.
- Meng X, Song S, Jiang ZF, et al. Receptor conversion in metastatic breast cancer: a prognosticator of survival. Oncotarget. 2016; 7(44).
